IOBT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.30%

Insider Buying (Last 12 Months): $4,950.00

Insider Selling (Last 12 Months): $1,860,484.74

IO Biotech Insider Trading History Chart

IO Biotech Share Price & Price History

^$0.84

▼ -0.05 (-5.59%)

As of 09/6/2024 01:00 AM ET

Days: 30 | 90 | 365

China Stockpiling Gold “Like No Tomorrow”

From True Gold Republic | Ad

For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .

Click here now to get your free 'De-Dollarization' Guide.

IO Biotech Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/25/2024	Holdings A/S Novo	Major Shareholder	Sell	51,522	$1.33	$68,524.26	4,377,927
5/10/2024	Holdings A/S Novo	Major Shareholder	Sell	658,809	$1.22	$803,746.98	4,429,449
2/9/2024	Holdings A/S Novo	Major Shareholder	Sell	658,809	$1.50	$988,213.50	5,088,258
11/21/2023	Brian Burkavage	CAO	Buy	5,000	$0.99	$4,950.00	6,500
8/9/2023	Vivo Capital Ix, Llc	Major Shareholder	Buy	3,157,894	$1.90	$5,999,998.60	3,157,894
3/17/2023	Amy Sullivan	CFO	Buy	25,000	$2.32	$58,000.00	25,000

War on Elon Escalates…

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

SEC Filings (Institutional Ownership Changes) for IO Biotech (NASDAQ:IOBT)

54.76% of IO Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

IO Biotech Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/20/2024	Novo Holdings A S	4,429,449	$5.18M	0.3%	-12.9%	6.723%
8/15/2024	Armistice Capital LLC	1,545,000	$1.81M	0.0%	-10.4%	2.345%
8/12/2024	XTX Topco Ltd	26,555	$31K	0.0%	+67.4%	0.040%
8/9/2024	Renaissance Technologies LLC	180,800	$0.21M	0.0%	+8.1%	0.274%
2/15/2024	PFM Health Sciences LP	2,341,107	$4.40M	0.3%	+73.0%	3.554%
2/13/2024	Stonepine Capital Management LLC	1,666,037	$3.13M	1.4%	-15.7%	2.529%
2/13/2024	Armistice Capital LLC	1,924,000	$3.62M	0.0%	-10.4%	2.920%
11/15/2023	Armistice Capital LLC	2,148,000	$3.03M	0.0%	N/A	3.260%
11/14/2023	Stonepine Capital Management LLC	1,975,308	$2.79M	0.9%	N/A	2.998%
11/14/2023	Pivotal bioVenture Partners Investment Advisor LLC	864,197	$1.22M	0.5%	N/A	1.312%
11/8/2023	Vivo Capital LLC	6,173,439	$8.71M	1.1%	+104.7%	9.371%
7/25/2023	Summit Trail Advisors LLC	43,744	$86K	0.0%	N/A	0.152%
2/14/2023	RA Capital Management L.P.	1,127,260	$2.59M	0.1%	-39.3%	3.911%
11/14/2022	Psagot Value Holdings Ltd. Israel	40,846	$0.11M	0.0%	N/A	0.142%
11/2/2022	Victory Capital Management Inc.	43,741	$0.12M	0.0%	N/A	0.152%
2/15/2022	Samsara BioCapital LLC	1,120,437	$7.17M	1.4%	N/A	3.888%
2/15/2022	Capital World Investors	1,235,000	$8.11M	0.0%	N/A	4.286%
2/14/2022	Soleus Capital Management L.P.	672,734	$4.31M	0.4%	N/A	2.335%
2/14/2022	Novo Holdings A S	3,277,932	$20.98M	1.0%	N/A	11.376%

Data available starting January 2016

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Today's Range

Now: $0.84

$0.80

$0.90

50 Day Range

MA: $1.35

$0.84

$1.64

52 Week Range

Now: $0.84

$0.80

$2.10

Volume

635,287 shs

Average Volume

150,213 shs

Market Capitalization

$55.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Who are the company insiders with the largest holdings of IO Biotech?: IO Biotech's top insider investors include:
Holdings A/S Novo (Major Shareholder)
Vivo Capital Ix, Llc (Major Shareholder)
Amy Sullivan (CFO)
Brian Burkavage (CAO)
Learn More about top insider investors at IO Biotech.
Who are the major institutional investors of IO Biotech?: IO Biotech's top institutional investors include:
Novo Holdings A S — 6.72%
Armistice Capital LLC — 2.35%
Renaissance Technologies LLC — 0.27%
XTX Topco Ltd — 0.04%
Learn More about top institutional investors of IO Biotech stock.
Which institutional investors are selling IO Biotech stock?: Within the last quarter, IOBT stock was sold by these institutional investors:
Novo Holdings A S
Armistice Capital LLC
Which institutional investors are buying IO Biotech stock?: In the previous quarter, IOBT stock was purchased by institutional investors including:
Renaissance Technologies LLC
XTX Topco Ltd
Within the last year, these company insiders have bought IO Biotech stock:
Holdings A/S Novo (Major Shareholder)
Vivo Capital Ix, Llc (Major Shareholder)
Amy Sullivan (CFO)
Learn More investors buying IO Biotech stock.